Skip to main content
Murali Janakiram, MD, Oncology, Duarte, CA, City of Hope Comprehensive Cancer Center

MuraliJanakiramMDMS

Oncology • Duarte, CA

HIV/AIDS Related, Hematologic Oncology

Associate Professor City of Hope

Telehealth Available

Request Appointment

Overview of Dr. Janakiram

Dr. Murali Janakiram is an oncologist at City of Hope, Duarte , CA who specializes in multiple myeloma, cellular therapy and immunotherapy.

Education & Training

  • Albert Einstein college of medicine
    Albert Einstein college of medicineMS, Clinical Research, 2012 - 2014
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2010 - 2013
  • The MetroHealth System/Case Western Reserve University
    The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 2007 - 2010
  • Madras Medical College
    Madras Medical CollegeClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2021 - 2025
  • MN State Medical License
    MN State Medical License 2018 - 2022
  • NY State Medical License
    NY State Medical License 2013 - 2020
  • OH State Medical License
    OH State Medical License 2007 - 2010

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multip...
    Murali Janakiram, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition
    Murali Janakiram, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Risk Stratification and Transfusion Dependence Are Independent Risk Factors for Cardiovascular Disease (CVD) in Myelodysplastic Syndrome (MDS)
    Murali Janakiram, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Differentiating Lung Involvement in Adult T-Cell Leukemia Lymphoma (ATLL) Versus HTLV Infection: Results from a Large Single-Center Cohort with Implications for Stagin... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Causes and Predictors of Early Mortality in HIV-Positive and HIV-Negative Patients with Diffuse Large B-Cell Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination with Ibrutinib
    ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination with IbrutinibJuly 17th, 2020
  • Doctors Warn Against Immunotherapy for Rare Blood Cancer
    Doctors Warn Against Immunotherapy for Rare Blood CancerJune 21st, 2018
  • Promising Cancer Treatment Which Made Patients Worse Shows How Far There Is to Go
    Promising Cancer Treatment Which Made Patients Worse Shows How Far There Is to GoJune 7th, 2018
  • Join now to see all

Hospital Affiliations

Dr. Murali Janakiram, Dr. Murali Janakiram, MD, Dr. M Janakiram